Search
Now showing items 141-150 of 169
Drug delivery across the blood-brain barrier using short-pulse focused ultrasound and microbubbles for the treatment of diffuse intrinsic pontine glioma
(Institute of Cancer Research (University Of London), 2023-09-01)
The blood-brain barrier (BBB) prevents unwanted substances from entering the brain, but also blocks entry of therapeutic agents, posing difficulties for treating brain cancers such as diffuse intrinsic pontine glioma (DIPG) ...
ctDNA guided diagnosis and management of gastrointestinal cancers
(Institute of Cancer Research (University Of London), 2023-07-05)
Gastrointestinal (GI) cancers including pancreatic (PC), biliary tract (BTC) and colorectal cancers (CRC) rely on a tissue biopsy through invasive procedures such as endoscopies and colonoscopies. Timely diagnosis of these ...
Unravelling the mechanisms of acquired immunomodulatory drug resistance in multiple myeloma
(Institute of Cancer Research (University Of London), 2023-12-01)
Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma
treatment and newer cereblon E3 ligase modulating drugs (CELMoDs) are in
clinical trials. However, a major barrier to improving patient outcomes is ...
Defining novel immune biomarkers of prognosis and immunotherapy sensitivity in gastro-oesophageal and colorectal cancers
(Institute of Cancer Research (University Of London), 2023-11-28)
Background
Gastro-oesophageal adenocarcinomas (GOAs) frequently recur after resection; prognostic and predictive markers are absent. Mismatch repair-deficient (MMRd) GOAs have high mutational burden, are frequently ...
Circulating tumour DNA analysis in advanced breast cancer
(Institute of Cancer Research (University Of London), 2022-10-17)
Circulating tumour DNA (ctDNA) analysis shows great potential both as an approach to understand the evolution of advanced breast cancer (ABC) and as a clinical tool to assist in ABC management. ctDNA analysis has not yet ...
Developing RAS-binding antibody-derived hit compounds
(Institute of Cancer Research (University Of London), 2023-09-27)
Dietary omega 6/3 fats and aspirin govern PI3Ka-induced oncogenicity
Oncogenic mutations in PI3KCA, the gene encoding the p110a catalytic subunit of PI3K, represent one of the most frequent genetic alterations in human cancer. Although multiple inhibitors of the PI3K/AKT/mTOR pathway have ...
Exploring an oncolytic virus triggered PD-L1 response via immunoPET
(Institute of Cancer Research (University Of London), 2023-01-23)
Oncolytic virotherapy (OV) exploits viruses which preferentially infect and kill cancerous cells. Moreover, oncolytic viruses stimulate the tumour-immune microenvironment towards an inflammatory phenotype. Therefore, OV ...
The structure and mechanism of the EXD2 nuclease in DNA repair
(Institute of Cancer Research (University Of London), 2023-06-09)
DNA double strand breaks (DSBs) are one of the most toxic DNA lesions. They can jeopardise stability of the genome and lead to cancer development. There are two main pathways of DSB repair: homologous recombination (HR) ...
Investigating the role of EXD2 in end resection, genome stability, and cancer
(Institute of Cancer Research (University Of London), 2023-06-26)
DNA double-strand breaks (DSBs) are highly toxic lesions, so their accurate repair is required to maintain genome stability and prevent human diseases, including cancer. DSBs are repaired by two main pathways: "error-prone" ...